Capital Reconstruction

Advanced Medical Solutions Grp PLC
23 July 2007


For immediate release                                             23 July 2007



                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')

                             Capital Reconstruction



  Reduction of the Company's share capital by the cancellation of its Deferred
 Shares of  5p each and the cancellation of the Company's share premium account





Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company today announces further progress in its Capital
Reconstruction that will enable it to pay a dividend in the future should the
Board make a recommendation to do so.





Further to the announcement of 6 June 2007, the Company announces that the High
Court of Justice confirmed the reduction of the Company's share capital by the
cancellation of its Deferred Shares of 5p each and the cancellation of the
Company's share premium account on 4 July 2007. The reduction and cancellation
became effective on 6 July 2007 on the registration by the Registrar of
Companies of the court order and of the minute approved by the court setting out
the particulars of the Company's share capital as altered by that order by
certificate given by the Registrar on 16 July 2007.

                                   -- ENDS --



For further information, please contact:


Advanced Medical Solutions Group plc                        [phone]
Don Evans (Chief Executive Officer)
Mary Tavener (Group Finance Director)
www.admedsol.com

Buchanan Communications                                    [phone]
Mark Court/Mary-Jane Johnson



Notes to Editors:



Advanced Medical Solutions is a UK based company developing and providing
leading edge technology to the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, the Company is focused on the design,
development, manufacture and sale of advanced woundcare dressings and products
for closing wounds and sealing tissue.

AMS provides a full range of advanced woundcare products for sale in hospital,
nursing home and community care markets.  The main indications are for chronic
wounds such as ulcers and pressure sores.  These products pioneer the concept of
moist wound healing to allow wounds to heal faster and with less pain and
scarring if they remain moist.  They protect the wound, deal with tissue fluids
and provide an optimal environment for healing to occur.   AMS' resources ensure
a unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products based upon
cyanoacrylate adhesive technology which allow the closure of wounds following
trauma or surgical incisions, or seal skin to protect against breakdown or wound
infection.  These products address the emerging tissue adhesives and sealants
segment of the wound closure market.



AMS' technology and products currently serve the majority of the key global
markets and strategic partners.






                      This information is provided by RNS
            The company news service from the London Stock Exchange